A detailed history of Ikarian Capital, LLC transactions in Lyra Therapeutics, Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 1,056,829 shares of LYRA stock, worth $295,912. This represents 0.12% of its overall portfolio holdings.

Number of Shares
1,056,829
Previous 1,056,829 -0.0%
Holding current value
$295,912
Previous $6.57 Million 95.51%
% of portfolio
0.12%
Previous 0.87%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$4.55 - $6.53 $898,875 - $1.29 Million
-197,555 Reduced 15.75%
1,056,829 $6.57 Million
Q3 2023

Nov 14, 2023

BUY
$2.95 - $4.8 $813,486 - $1.32 Million
275,758 Added 28.18%
1,254,384 $4.9 Million
Q2 2023

Aug 14, 2023

BUY
$1.98 - $4.33 $1.26 Million - $2.75 Million
634,941 Added 184.75%
978,626 $4.02 Million
Q3 2022

Nov 14, 2022

SELL
$4.95 - $6.6 $18,082 - $24,109
-3,653 Reduced 1.05%
343,685 $1.72 Million
Q2 2022

Aug 12, 2022

SELL
$4.12 - $7.51 $309,000 - $563,250
-75,000 Reduced 17.76%
347,338 $1.96 Million
Q1 2022

May 13, 2022

BUY
$3.5 - $5.36 $97,307 - $149,018
27,802 Added 7.05%
422,338 $1.7 Million
Q4 2021

Feb 14, 2022

SELL
$4.22 - $9.41 $37,617 - $83,880
-8,914 Reduced 2.21%
394,536 $1.72 Million
Q3 2021

Nov 15, 2021

SELL
$6.06 - $9.43 $1.34 Million - $2.09 Million
-221,234 Reduced 35.42%
403,450 $3.69 Million
Q2 2021

Aug 16, 2021

SELL
$6.91 - $12.59 $1.08 Million - $1.96 Million
-156,044 Reduced 19.99%
624,684 $5.02 Million
Q1 2021

May 17, 2021

SELL
$10.38 - $15.61 $359,521 - $540,667
-34,636 Reduced 4.25%
780,728 $9.05 Million
Q4 2020

Feb 12, 2021

BUY
$9.28 - $13.88 $3.97 Million - $5.93 Million
427,425 Added 110.18%
815,364 $9.3 Million
Q3 2020

Nov 16, 2020

BUY
$10.61 - $13.96 $4.12 Million - $5.42 Million
387,939 New
387,939 $4.34 Million

Others Institutions Holding LYRA

About Lyra Therapeutics, Inc.


  • Ticker LYRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,826,400
  • Market Cap $8.91M
  • Description
  • Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...
More about LYRA
Track This Portfolio

Track Ikarian Capital, LLC Portfolio

Follow Ikarian Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.